SCI Pharmtech Inc (4119) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SCI Pharmtech Inc (4119) has a cash flow conversion efficiency ratio of -0.006x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-32.67 Million ≈ $-1.03 Million USD) by net assets (NT$5.37 Billion ≈ $169.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SCI Pharmtech Inc - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how SCI Pharmtech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of SCI Pharmtech Inc for a breakdown of total debt and financial obligations.
SCI Pharmtech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SCI Pharmtech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Paragon Care Ltd
AU:PGC
|
-0.088x |
|
Atlantic Lithium Ltd
AU:A11
|
-0.046x |
|
Malayan Flour Mills Bhd
KLSE:3662
|
0.098x |
|
Hocheng Corp
TW:1810
|
0.018x |
|
Shanghai Highly Group Co Ltd B
SHG:900910
|
0.026x |
|
Ugro Capital Limited
NSE:UGROCAP
|
0.007x |
|
PHA Co. Ltd
KQ:043370
|
0.033x |
|
Aimia Inc
TO:AIM
|
0.110x |
Annual Cash Flow Conversion Efficiency for SCI Pharmtech Inc (2002–2024)
The table below shows the annual cash flow conversion efficiency of SCI Pharmtech Inc from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see SCI Pharmtech Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.48 Billion ≈ $172.55 Million |
NT$860.52 Million ≈ $27.11 Million |
0.157x | +271.37% |
| 2023-12-31 | NT$5.10 Billion ≈ $160.68 Million |
NT$215.77 Million ≈ $6.80 Million |
0.042x | -48.23% |
| 2022-12-31 | NT$3.63 Billion ≈ $114.34 Million |
NT$296.56 Million ≈ $9.34 Million |
0.082x | -3.19% |
| 2021-12-31 | NT$3.32 Billion ≈ $104.62 Million |
NT$280.28 Million ≈ $8.83 Million |
0.084x | -71.14% |
| 2020-12-31 | NT$3.32 Billion ≈ $104.67 Million |
NT$971.53 Million ≈ $30.61 Million |
0.292x | +28.36% |
| 2019-12-31 | NT$3.47 Billion ≈ $109.47 Million |
NT$791.60 Million ≈ $24.94 Million |
0.228x | +52.31% |
| 2018-12-31 | NT$3.21 Billion ≈ $101.14 Million |
NT$480.18 Million ≈ $15.13 Million |
0.150x | +55.59% |
| 2017-12-31 | NT$2.93 Billion ≈ $92.30 Million |
NT$281.65 Million ≈ $8.87 Million |
0.096x | -41.20% |
| 2016-12-31 | NT$3.07 Billion ≈ $96.75 Million |
NT$502.11 Million ≈ $15.82 Million |
0.164x | -31.91% |
| 2015-12-31 | NT$2.76 Billion ≈ $87.02 Million |
NT$663.24 Million ≈ $20.90 Million |
0.240x | +49.00% |
| 2014-12-31 | NT$2.23 Billion ≈ $70.14 Million |
NT$358.77 Million ≈ $11.30 Million |
0.161x | +39.69% |
| 2013-12-31 | NT$2.07 Billion ≈ $65.15 Million |
NT$238.57 Million ≈ $7.52 Million |
0.115x | -62.24% |
| 2012-12-31 | NT$1.26 Billion ≈ $39.76 Million |
NT$385.57 Million ≈ $12.15 Million |
0.306x | +38.51% |
| 2011-12-31 | NT$1.13 Billion ≈ $35.64 Million |
NT$249.55 Million ≈ $7.86 Million |
0.221x | +13.97% |
| 2010-12-31 | NT$1.13 Billion ≈ $35.64 Million |
NT$218.96 Million ≈ $6.90 Million |
0.194x | -36.62% |
| 2009-12-31 | NT$1.04 Billion ≈ $32.70 Million |
NT$316.96 Million ≈ $9.99 Million |
0.305x | +17.35% |
| 2008-12-31 | NT$942.51 Million ≈ $29.69 Million |
NT$245.29 Million ≈ $7.73 Million |
0.260x | +37.66% |
| 2007-12-31 | NT$886.14 Million ≈ $27.92 Million |
NT$167.53 Million ≈ $5.28 Million |
0.189x | +11.61% |
| 2006-12-31 | NT$777.01 Million ≈ $24.48 Million |
NT$131.62 Million ≈ $4.15 Million |
0.169x | +69.60% |
| 2004-12-31 | NT$767.10 Million ≈ $24.17 Million |
NT$76.61 Million ≈ $2.41 Million |
0.100x | -63.76% |
| 2003-12-31 | NT$750.63 Million ≈ $23.65 Million |
NT$206.86 Million ≈ $6.52 Million |
0.276x | +40.49% |
| 2002-12-31 | NT$546.06 Million ≈ $17.20 Million |
NT$107.12 Million ≈ $3.37 Million |
0.196x | -- |
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more